Westfield Capital Management Co. LP Acquires 165,911 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Westfield Capital Management Co. LP increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,493,833 shares of the biotechnology company's stock after acquiring an additional 165,911 shares during the period. Westfield Capital Management Co. LP owned about 4.94% of Rocket Pharmaceuticals worth $83,001,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Novo Holdings A S raised its holdings in Rocket Pharmaceuticals by 4.8% in the 2nd quarter. Novo Holdings A S now owns 1,100,000 shares of the biotechnology company's stock worth $23,683,000 after acquiring an additional 50,000 shares during the period. Renaissance Technologies LLC acquired a new position in Rocket Pharmaceuticals in the 2nd quarter valued at approximately $2,144,000. First Turn Management LLC lifted its position in shares of Rocket Pharmaceuticals by 10.8% in the 3rd quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company's stock worth $11,476,000 after acquiring an additional 60,317 shares during the period. Maverick Capital Ltd. grew its holdings in shares of Rocket Pharmaceuticals by 1.0% during the 2nd quarter. Maverick Capital Ltd. now owns 3,928,312 shares of the biotechnology company's stock worth $84,577,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Privium Fund Management B.V. increased its position in shares of Rocket Pharmaceuticals by 17.5% during the third quarter. Privium Fund Management B.V. now owns 294,800 shares of the biotechnology company's stock valued at $5,445,000 after purchasing an additional 43,820 shares during the period. Institutional investors and hedge funds own 98.39% of the company's stock.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT traded up $1.32 during trading hours on Friday, hitting $14.11. The company had a trading volume of 1,194,045 shares, compared to its average volume of 910,721. Rocket Pharmaceuticals, Inc. has a 12 month low of $12.62 and a 12 month high of $32.53. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -5.13 and a beta of 1.09. The business has a fifty day moving average of $17.15 and a 200-day moving average of $19.83. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Analysts Set New Price Targets

Several research analysts recently commented on RCKT shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $52.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Scotiabank assumed coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $50.00 price target for the company. Leerink Partners cut their price target on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, November 19th. Chardan Capital reiterated a "buy" rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. raised their target price on Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $51.00.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.